Compare ADMA Biologics Inc (ADMA) vs MPLX LP (MPLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs MPLX LP — how do they compare? ADMA Biologics Inc trades at $9.91 (market cap $2.22B), while MPLX LP trades at $59.88 (market cap $60.12B). The key difference: MPLX LP is far larger — about 27.1× ADMA Biologics Inc's market cap, and MPLX LP pays a 7.26% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | MPLX | |
|---|---|---|
Market Cap | $2.22B | $60.12B |
Sector | Health | Technology |
52-Week High | $20.38 | $60.51 |
52-Week Low | $7.60 | $47.80 |
Enterprise Value | $2.29B | $85.22B |
Dividend Yield | — | 7.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.
The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.
MPLX trades at $59.75, up 1.79% today, with a bullish technical signal from moving averages and support near $59. The company reported strong 2025 results with $11.47B revenue and $4.91B net income, though Q1 and Q2 2026 EPS missed expectations. Recent news highlights a $2.25B senior notes offering (PRNewsWire, Aug 10, 2026) and solid Q2 performance driven by natural gas and NGL volume growth.
Outlook remains positive with a 67.86% analyst buy rating and $61.50 consensus price target, offering potential upside. Key opportunities include fee-based revenue stability and dividend growth, while risks involve higher capital spending and execution challenges on growth projects. The stock presents a balanced profile for income-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →
